A Randomized, Open Label Intra-patient Dose Escalation Study With an Untreated Reference Group to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Infusions of BPS804 in Adults With Moderate Osteogenesis Imperfecta
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Setrusumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors Novartis; Ultragenyx Pharmaceutical
- 10 Jun 2014 New trial record